Volume | 3,453 |
|
|||||
News | - | ||||||
Day High | 3.29 | Low High |
|||||
Day Low | 3.17 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
GT Biopharma Inc | GTBP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.29 | 3.17 | 3.29 | 3.22 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
69 | 3,453 | $ 3.22 | $ 11,135 | - | 2.9539 - 16.11 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
13:40:08 | 34 | $ 3.25 | USD |
GT Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
4.42M | 1.38M | - | 0 | -7.6M | -5.50 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
GT Biopharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GTBP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.06 | 3.4999 | 2.9539 | 3.15 | 6,838 | 0.14 | 4.58% |
1 Month | 4.10 | 4.38 | 2.9539 | 3.61 | 6,852 | -0.90 | -21.95% |
3 Months | 4.3814 | 5.21 | 2.9539 | 4.25 | 12,681 | -1.18 | -26.96% |
6 Months | 8.301 | 8.70 | 2.9539 | 6.73 | 78,476 | -5.10 | -61.45% |
1 Year | 9.45 | 16.11 | 2.9539 | 8.59 | 221,779 | -6.25 | -66.14% |
3 Years | 482.70 | 591.993 | 2.9539 | 129.33 | 208,302 | -479.50 | -99.34% |
5 Years | 165.00 | 591.993 | 2.9539 | 154.31 | 243,149 | -161.80 | -98.06% |
GT Biopharma Description
GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. |